CHEMOMAB THERAPEUTICS LTD

CMMBNASDAQ

🏆 #3696 by market capEarnings Aug 13US Equity

$1.90▲ $0.01 (+0.53%)

Market closed · at close

1h—

24h▲ 0.5%

7d▲ 8.6%

14d▲ 23.8%

30d▲ 19.5%

1y▼ 48.4%

🏦Market Cap

$12M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $1.88 – $1.92
52-Week Range: $1.35 – $4.12
Volume: $3.57B
Avg Volume: $3.11B
Shares Outstanding: 6.2M
Next Earnings: Sep 2, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $552,495
P/E Ratio: -1.7
P/S Ratio: 0.0x
EPS (TTM): $-0.93
Dividend Yield: 0.00%

Why Investors Own CMMB

✓High-growth profile — revenue up +35.3% YoY with expanding US Equity exposure.
✓Healthy economics — 67% gross margin and 29% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +29.0% YoY

Gross Margin (TTM)

66.5%▲ +0.2% YoY

Operating Income (TTM)

$223,984▲ +29.0% YoY

Free Cash Flow (TTM)

$570,861▲ +29.0% YoY

About CHEMOMAB THERAPEUTICS LTD

Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

🦦